A Unified Framework for Classifying Nano‑Enabled Health Products
Nanotechnology-enabled health products (NHPs) occupy a fast-growing but unevenly regulated space at the intersection of materials science, medicine, and engineering. Despite a projected market expansion from USD 53 billion in 2009 to roughly USD 334 billion by 2025, the path from laboratory innovation to patient access remains hindered by regulatory fragmentation. The disparity between the tens of thousands of publications and patents in the field and the comparatively small number of approved products is emblematic of the so‑called “valley of death” in translational research.
A central challenge lies in the absence of harmonized definitions and classification systems. Regulatory bodies in the United States, European Economic Area, and elsewhere differ in their thresholds for what constitutes a nanomaterial. For example, the European Commission’s 2022 recommendation limits the definition to materials with at least 50% of particles in the 1–100 nm range, while U.S. FDA guidance allows flexibility up to 1,000 nm. Such variations complicate the interoperability of stakeholders and the applicability of guidelines.
To address this, a new classification system has been proposed that integrates both scientific and regulatory considerations. It is built on four criteria: principal mode of action, chemical composition of the nanoparticle core, medical purpose, and nanomanufacturing approach. The first criterion distinguishes whether the product’s primary effect is pharmacological, immunological, or metabolic—aligning it more closely with medicinal products—or whether it operates through physical or mechanical means, characteristic of medical devices. This distinction is fundamental to determining applicable legislative frameworks.
The second criterion, chemical composition, draws from ISO/TR 11360:2010 categories: ceramic, metallic, semi-metallic, polymeric (natural or synthetic), and carbon-based. These are further grouped by colloidal behavior—dispersoid, molecular, or associated colloids—reflecting differences in stability, hydrophilicity, and biological interaction. Notably, the classification favors qualitative descriptors over quantitative thresholds, given the lack of scientific consensus on fixed nanoscale size limits.
Medical purpose forms the third criterion, encompassing pharmacological therapeutic, pharmacological prophylactic, non-pharmacological therapeutic, diagnostic (in vitro or in vivo), and technological or galenic functions. This aligns with regulatory expectations for demonstrating efficacy and performance, whether through pre-clinical models or clinical trials.
The fourth criterion addresses nanomanufacturing approach, distinguishing top-down from bottom-up synthesis. Top-down methods, which break down bulk materials, tend to generate more waste, while bottom-up approaches can incorporate green nanotechnology principles, using biological processes to produce biocompatible, energy-efficient, and potentially biodegradable nanomaterials. Given increasing regulatory attention to environmental risk, this dimension adds sustainability and occupational safety considerations to classification.
Each NHP can be assigned a four-part alphanumeric “classification signature” corresponding to its attributes under these criteria. For example, a non-pharmacological silver nanoparticle diagnostic manufactured via bottom-up synthesis would be coded 2.1.2.1. The system also accommodates multi-functional products, such as theranostics, by allowing dual codes for relevant criteria.
Beyond products, the same framework can classify regulatory documents, revealing whether they are broad in scope or tailored to specific NHP types. Analysis of a compiled database of guidelines from the EMA, FDA, OECD, ISO, and ASTM shows that published documents tend to be more general, while those under development are increasingly specific—a trend paralleling the evolution of advanced therapy medicinal products regulation.
This specialization reflects a shift in regulatory science toward recognizing that nanoparticles are not merely scaled-down bulk materials but possess distinct physicochemical and biological behaviors. The OECD’s 2022 report on manufactured nanomaterials underscores the need for case-by-case risk assessment, even as general methodologies are desirable. By mapping classification signatures against existing and emerging guidelines, regulators can identify gaps and anticipate future needs through tools such as Horizon Scanning.
For developers and manufacturers, the classification system offers a way to align product design and testing strategies with applicable regulatory expectations from the outset. Integrated into a searchable platform, it could return relevant guidelines for a given NHP signature, from general standards to highly specific technical requirements. Such alignment has the potential to reduce attrition in late-stage development, narrow the valley of death, and accelerate the safe, effective introduction of nano-enabled health technologies into clinical use.
